Tags : NVX-CoV2373

Biotech COVID-19

SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19

Shots: SK bioscience signs a development and supply agreement for Novavax’ NVX-CoV2373 to supply it globally including the COVAX facility. SK bioscience will manufacture the vaccine antigen component for use in the final drug product SK bioscience will utilize its cell culture and recombinant protein capability, will initiate the production of the NVX-CoV2373 antigen at […]Read More

COVID-19 Pharma

Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to

Shots: Novavax has identified a coronavirus vaccine candidate, NVX-CoV2373 utilizing its nanoparticle technology and will initiate a first-in-human trial in mid-May with its anticipated immunogenicity and safety results in July. Novavax will integrate its Matrix-M adjuvant with NVX-CoV2373 to improve the immune response stimulates high levels of neutralizing Ab The company plans to combine P-I/II […]Read More